Healthcare
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience
About this update from Ibio, Inc.
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development. Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University and the University of Washington. Most recently, she served as Clinical Head and Associate Vice President of Lilly's Insulin and Glucagon Franchise, where she oversaw the company's insulin portfolio and clinical development team, including the Phase 3 program for efsitora, a once-weekly insulin, as well as programs spanning prandial insulin, nasal glucagon, biosimilars and legacy insulins. Dr. Carr earned her M.D. from Columbia University College of Physicians and Surgeons and completed her residency and fellowship in endocrinology at the University of Washington. "Adding Molly to our leadership team is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic," said Martin Brenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. "Her rare combination of deep scientific expertise in endocrinology and metabolic disease, together with hands-on experience leading clinical programs across all stages of development, will be invaluable as we advance IBIO-600 and IBIO-610 into their next clinical phases. Her appointment reflects iBio's growth into a clinical-stage company and strengthens our ability to execute on our programs with the rigor and focus required to bring them closer to patients." "The science behind iBio's clinical candidates is closely aligned with my experience in endocrinology, obesity, muscle biology and cardiomet...